Demystifying Macrogenics: Insights From 14 Analyst Reviews
Portfolio Pulse from Benzinga Insights
Analysts' ratings for Macrogenics (NASDAQ:MGNX) show mixed sentiments over the last quarter, with a range of bullish to bearish views. The average 12-month price target has decreased to $17.57 from $18.93. Recent analyst actions include both downgrades and upgrades, reflecting dynamic market conditions and company performance. Macrogenics faces financial challenges, including a significant revenue decline and below-average ROE and ROA, but maintains a sound debt-to-equity ratio.
May 24, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Macrogenics (NASDAQ:MGNX) has received mixed analyst ratings over the last quarter, with a decrease in the average 12-month price target to $17.57. The company faces financial challenges, including a significant revenue decline and below-average ROE and ROA, but maintains a sound debt-to-equity ratio.
The mixed analyst ratings and the decrease in the average price target indicate uncertainty about Macrogenics' short-term performance. Financial challenges such as revenue decline and low ROE and ROA further contribute to this uncertainty, although the company's sound debt-to-equity ratio is a positive factor.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100